• Todd P. Stitik
  • Jong H. Kim
  • Gregory Gazzillo
  • Charles Lee


Viscosupplementation is the intra-articular (IA) injection of hyaluronic acid (HA, aka hyaluronans, sodium hyaluronans, or hyaluronates) into synovial joints for the relief of osteoarthritic pain. HAs are only FDA approved for the treatment of pain associated with knee osteoarthritis (OA). In contrast, outside the US, HAs are generally approved for the treatment of pain of OA in all joints. Because evidence is accumulating to support the use of HAs in joints in addition to the knee, FDA approval for use in other joints, particularly the hips, may be forthcoming.


Total Knee Replacement Joint Space Narrowing Joint Space Width Sodium Hyaluronate Anterior Cruciate Ligament Transection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Special thanks to Michael J. Daly, PhD, who contributed to the content of this chapter.


  1. 1.
    Gotoh S. Miyazaki K, Onaya J, Sakamoto T, Tokuyasu K, Namiki O. Experimental knee pain model in rats and analgesic effect of sodium hyaluronate. Folia Pharm 1988;92:17–27.Google Scholar
  2. 2.
    Engstrom-Laurent A. Hyaluronan in joint disease. J Intern Med 1997;242:57–60.PubMedGoogle Scholar
  3. 3.
    Balazs EA. Sediment volume and viscoelastic behavior of hyaluronic acid solutions. Fed Proc 1966;25(6):1817–22.PubMedGoogle Scholar
  4. 4.
    Altman D. Laboratory Findings in Osteoarthritis. In Moskowitz, HD, Goldberg V, Mankin J, eds. Osteoarthritis-Diagnosis and Medical Surgical Management, Second ed. Philadelphia, PA: WB Saunders; 1992:313–28.Google Scholar
  5. 5.
    Balazs EA. The Physical Properties of Synovial Fluid and the Special Role of Hyaluronic Acid. In Helfet A, ed. Disorders of the Knee. Philadelphia, PA: Lippincott; 1974:61–74.Google Scholar
  6. 6.
    Dougados M. High molecular weight sodium hyauronate in Knee OA: 1-Year placebo-controlled trial. Osteoarthr Cartil 1993;1:97–103.PubMedGoogle Scholar
  7. 7.
    Greenberg DD, Stoker A, Kane S, Cockrell M, Cook JL. Biochemical effects of two different hyaluronic acid products in a co-culture model of osteoarthritis. Osteoarthr Cartil 2006; 14(8):814–22. Epub 2006 April 17.PubMedGoogle Scholar
  8. 8.
    Smith MM, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment.Rheumatol Int 1987;7(3):113–22.PubMedGoogle Scholar
  9. 9.
    Ishida O, Tanaka Y, Morimoto I, Takigawa M, Eto S. Chondrocytes are regulated by cellular adhesion through CD44 and hyaluronic acid pathway. J Bone Miner Res 1997;12:1657–63.PubMedGoogle Scholar
  10. 10.
    Vuorio E, Einola S, Hakkarainen S, Penttinen R. Synthesis of under-polymerised hyaluronic acid by fibroblasts cultured from rheumatoid and non-rheumatoid synovitis. Rheumatol Int 1982;2:97–102.PubMedGoogle Scholar
  11. 11.
    Peyron JG, Balazs EA. Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joints. Pathol Biol 1976;22:731–6.Google Scholar
  12. 12.
    Balazs EA, Denlinger JL. Sodium hyaluronic acid and joint function. J Equine Vet Sci 1985;5:217–28.Google Scholar
  13. 13.
    Auer JA, Fackelman GE, Gingerich DA, Fetter AW. Effect of hyaluronic acid in naturally occurring and experimentally induced osteoarthritis. Am J Vet Res 1980;41:568–74.PubMedGoogle Scholar
  14. 14.
    Rydell NW, Butler J, Balazs EA. Hyaluronic acid in synovial fluid. VI: Effect if intra-articular injection of hyaluronic acid on the clinical symptoms of arthritis in track horses. Acta Vet Scand 1970;11:139–55.PubMedGoogle Scholar
  15. 15.
    Rydell N, Balazs E. Effect of intro-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. Clin Orthop Rel Res 1971;80:25–32.Google Scholar
  16. 16.
    Asheim A, Lindblad G. Intra-articular treatment of arthritis in race-horses with sodium hyaluronate. Acta Vet Scand 1976;17(4):379–94.PubMedGoogle Scholar
  17. 17.
    Phillips MW. Clinical trial comparison of intra-articular sodium hyaluronate products in the horse. J. Equine Vet Sci 1989;9:39–40.Google Scholar
  18. 18.
    Gingerich DA, Auer JA, Fackerman CE. Effects of exogenous hyaluronic acid on joint ­function in experimentally induced equine osteoarthritis: dosage titration studies. Res Vet Sci 1981;30:192–7.PubMedGoogle Scholar
  19. 19.
    Peterfy C, Kothari M. Imaging osteoarthritis: magnetic resonance imaging versus x-ray. Curr Rheumatol Rep 2006;8(1):16–21.PubMedGoogle Scholar
  20. 20.
    Stitik TP, Levy JA. Viscosupplementation (biosupplementation) for osteoarthritis. Am J Phys Med Rehabil 2006;85(11 Suppl):S32–50.PubMedGoogle Scholar
  21. 21.
    Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006;19(2):CD005321.Google Scholar
  22. 22.
    Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000 Sep;43(9):1905–15.Google Scholar
  23. 23.
    Kelly MA, Goldberg VM, Healy WL, Pagnano MW, Hamburger MI. Osteoarthritis and beyond: a concensus on the past, present, and future of hyaluronans in orthopedics. Orthopedics 2003;26:1064–81.PubMedGoogle Scholar
  24. 24.
    Neustadt DH. Long-term efficacy and safety of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee. Clin Exp Rheumatol 2003;21(3):307–11.PubMedGoogle Scholar
  25. 25.
    Neustadt DH. Long-term efficacy and safety of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee. Clin Exp Rheumatol 2003;21(3):307–11.PubMedGoogle Scholar
  26. 26.
    Kolarz G, Kotz R, Hochmayer I. Long-term benefits and repeated treatment cycles of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee. Semin Arthritis Rheum 2003;32(5):310–9.PubMedGoogle Scholar
  27. 27.
    Karlsson J, Sjögren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford) 2002;41(11):1240–8.Google Scholar
  28. 28.
    Waddell DD, Cefalu CA, Bricker DC. A second course of hylan G-F 20 for the treatment of osteoarthritic knee pain: 12-month patient follow-up. J Knee Surg 2005;18(1):7–15.PubMedGoogle Scholar
  29. 29.
    Stitik TP, Foye PM, Nadler SF, Chen B, Stiskal DM, Schoenherr L. Intra-articular Hyaluronan therapy and concomitant home exercise strengthening – an additive therapeutic algorithm for osteoarthritis of the knee. Arch Phys Med Rehabil 2004;85(9):e9.Google Scholar
  30. 30.
    Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthr Cartil 2002 Jul;10(7):506–17.PubMedGoogle Scholar
  31. 31.
    Bayramoglu M, Karataş M, Cetin N, Akman N, Sözay S, Dilek A. Comparison of two different viscosupplements in knee osteoarthritis – a pilot study. Clin Rheumatol 2003;22(2):118–22.PubMedGoogle Scholar
  32. 32.
    Huang MH, Yang RC, Lee CL, Chen TW, Wang MC. Preliminary results of integrated therapy for patients with knee osteoarthritis. Arthritis Rheum 2005;53(6):812–20.PubMedGoogle Scholar
  33. 33.
    Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006;2:CD005328.PubMedGoogle Scholar
  34. 34.
    Tang SF, Chen CPC, Chen MJL, Hong W-H, Yu T-Y, Tsai W-C. Improvement of muscle strength in osteoarthritic knee patients after intraarticular knee injection of hyaluronan. Am J Phys Med Rehabil 2005;84(4):274–7.PubMedGoogle Scholar
  35. 35.
    Felson DT. Nonmedical Therapies for Osteoarthritis. Bull Rheum Dis 1998;47(2):5–7.PubMedGoogle Scholar
  36. 36.
    Chamberlain MA, Care G, Harfield B. Physiotherapy in osteoarthritis of the knees: a controlled trial of hospital versus home exercises. Int Rehabil Med 1982;4:101–6.PubMedGoogle Scholar
  37. 37.
    Feinberg J, Marzouk D, Sokolek C, Katz B, Bradley J, Brandt K. Effects of isometric versus range of motion exercise on joint pain and function in patients with knee osteoarthritis (abstract). Arthritis Rheum 1992;35 (suppl 5):R28.Google Scholar
  38. 38.
    Jan MH, Lai JS. The effects of physiotherapy on osteoarthritic knees of females. J Formos Med Assoc 1993;90:1008–13.Google Scholar
  39. 39.
    Yavuzer G, Sonel B, Süldür N, Ergin S. Effects of intra-articular hylan G-F 20 injections on clinical and biomechanical characteristics of the knee in osteoarthritis. Int J Rehabil Res 2005;28(4):371–4.PubMedGoogle Scholar
  40. 40.
    Vad VB, Bhat AL, Sculco TP, Wickiewicz TL. Management of knee osteoarthritis: knee lavage combined with hylan versus hylan alone. Arch Phys Med Rehabil 2003;84(5):634–7.PubMedGoogle Scholar
  41. 41.
    Forster MC, Straw R. A prospective randomised trial comparing intra-articular Hyalgan injection and arthroscopic washout for knee osteoarthritis. Knee 2003;10(3):291–3.PubMedGoogle Scholar
  42. 42.
    Petrella RJ. Hyaluronic acid for the treatment of knee osteoarthritis: long-term outcomes from a naturalistic primary care experience. Am J Phys Med Rehabil 2005;84(4):278–83.PubMedGoogle Scholar
  43. 43.
    Scali JJ. Intra-articular sodium hyaluronic acid in the treatment of osteoarthritis of the knee: a long term study. Eur J Rheumatol Inflamm 1995;15(1):57–62.Google Scholar
  44. 44.
    “Osteoarthritis” Filmed: Newark, N.J 5/17/07. “Healthy Body, Healthy Mind” Series on Public Broadcast System.
  45. 45.
    Conrozier T, Mathieu P, Schott A-M, Laurent I, Hajri T, Crozes P et al. Factors predicting long-term efficacy of Hylan GF-20 viscosupplementation in knee osteoarthritis. Joint Bone Spine 2003;70(2):128–33.PubMedGoogle Scholar
  46. 46.
    Toh EM, Prasad PS, Teanby D. Correlating the efficacy of knee viscosupplementation with osteoarthritic changes on roentgenological examination. Knee 2002;9(4):321–30.PubMedGoogle Scholar
  47. 47.
    Hamburger MI, Lakhanpal S, Mooar PA, Oster D. Intra-articular hyaluronans: a review of product-specific safety profiles. Semin Arthritis Rheum 2003;32(5):296–309.PubMedGoogle Scholar
  48. 48.
    Espallargues M, Pons JM. Efficacy and safety of viscosupplementation with Hylan G-F 20 for the treatment of knee osteoarthritis: a systematic review. Int J Technol Assess Health Care 2003;19(1):41–56.PubMedGoogle Scholar
  49. 49.
    Hammesfahr JF, Knopf AB, Stitik T. Safety of intra-articular hyaluronates for pain associated with osteoarthritis of the knee. Am J Orthop 2003;32(6):277–83.PubMedGoogle Scholar
  50. 50.
    Pagnano M, Westrich G. Successful nonoperative management of chronic osteoarthritis pain of the knee: safety and efficacy of retreatment with intra-articular hyaluronans. Osteoarthr Cartil 2005;13(9):751–61.PubMedGoogle Scholar
  51. 51.
    Goldberg VM, Coutts RD. Pseudoseptic reactions to hylan viscosupplementation: diagnosis and treatment. Clin Orthop 2004;419:130–7.PubMedGoogle Scholar
  52. 52.
    Hamburger M, Settles M, Teutsch J. Identification of an immunogenic candidate for the elicitation of severe acute inflammatory reactions (SAIRs) to hylan G-F 20. Osteoarthr Cartil 2005;13(3):266–8.PubMedGoogle Scholar
  53. 53.
    Chen AL, Desai P, Adler EM, Di Cesare PE. Granulomatous inflammation after Hylan G-F 20 viscosupplementation of the knee: a report of six cases. J Bone Joint Surg Am 2002;84-A:1142–7.PubMedGoogle Scholar
  54. 54.
    Jones KB, Patel PP, Deyoung BR, Buckwalter JA. Viscosupplementation pseudotumor. A case report. J Bone Joint Surg Am 2005;87:1113–9.PubMedGoogle Scholar
  55. 55.
    Sodium hyaluronate (MW 500–730 kDa) product labeling.Google Scholar
  56. 56.
    Personal communication with Roland J. Moskowitz, MD.Google Scholar
  57. 57.
    Frizziero L, Govoni E, Bacchini P. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: clinical and morphological study. Clin Exp Rheumatol 1998;16(4):441–9.PubMedGoogle Scholar
  58. 58.
    Kikuchi T, Yamada H, Shimmei M. Effect of high molecular weight hyaluronan on cartilage degradation in a rabbit model of osteoarthritis. Osteoarthr Cartil 1996;4:99–110.PubMedGoogle Scholar
  59. 59.
    Jubb RW, Piva S., Beinat L, Dacre J, Gishen P. A randomised, placebo (saline)-controlled clinical trial of the structure modifying effect of 500–730 KDa sodium hyaluronate (Hyalgan) in osteoarthritis of the knee. Int J Clin Pract 2003;57:467–74.PubMedGoogle Scholar
  60. 60.
    Listrat V, Ayral X, Patarnello F, Bonvarlet JP, Simonnet J, Amor B. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (hyalgan) in osteoarthritis of the knee. Osteoarthr Cartil 1997;5:153–60.PubMedGoogle Scholar
  61. 61.
    Carrabba M, Paresce E, Angelini M, Re KA, Torchiaa EEM, Perbellini A. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. Eur J Rheumatol Inflamm 1995;15:25–31.Google Scholar
  62. 62.
    Guidolin DD, Ronchetti IP, Lini E, Guerra D, Frizziero L. Morphological analysis of articular cartilage biopsies from a randomized, clinical study comparing the effects of 500–730 kDa sodium hyaluronate (Hyalgan) and methylprednisolone acetate on primary osteoarthritis of the knee. Osteoarthr Cartil 2001;9:371–81.PubMedGoogle Scholar
  63. 63.
    Jubb RW, Piva S, Beinat L, Dacre J, Gishen P, for the UK Hyalgan study group. Clinical trial to examine the effect of HA on articular cartilage through changes in radiological joint space. Presented at: Annual European Congress of Rheumatology European League against Rheumatology. June 13–16, 2001. Prague, Czech Republic.Google Scholar
  64. 64.
    Marshall KW, Manolopoulos V, Mancer K, Staples J, Damyanovich A. Amelioration of disease severity by intraarticular hylan therapy in bilateral canine osteoarthritis. J Orthop Res 2000;18:416–25.PubMedGoogle Scholar
  65. 65.
    Shimizu C, Yoshioka M, Coutts RD, Harwood FL, Kubo T, Hirasawa Y et al. Long-term effects of hyaluronans on experimental osteoarthritis in a rabbit knee. Osteoarthr Cartil 1998;6:1–9.PubMedGoogle Scholar
  66. 66.
    Goldberg VM, Buckwalter JA. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthr Cartil 2005;13(3):216–24.PubMedGoogle Scholar
  67. 67.
    Kawasaki K, Ochi M, Uchio Y, Adachi N, Matsusaki M. Hyaluronic acid enhances proliferation and chondroitin sulfate synthesis in cultured chondrocytes embedded in collagen gels. J Cell Physiol 1999;179:142–8.PubMedGoogle Scholar
  68. 68.
    Fukuda K, Dan H, Takayama M, Kumano F, Saitoh M, Tanaka S. Hyaluronic acid increases proteoglycan synthesis in bovine articular cartilage in the presence of ­interleukin-1. J Pharmacol Exp Ther 1996;277(3):1672–5.PubMedGoogle Scholar
  69. 69.
    Stove J, Gerlach C, Huch K, Gunther KP, Puhl W, Scharf HP. Effects of hyaluronan on proteoglycan content of osteoarthritic chondrocytes in vitro. J Orthop Res 2002;20:551–5.PubMedGoogle Scholar
  70. 70.
    Ghosh P, Holbert C, Read R, Armstrong S. Hyaluronic acid (hyaluronan) in experimental osteoarthritis. J Rheumatol Suppl 1995;43:155–7.PubMedGoogle Scholar
  71. 71.
    Creamer P, Sharif M, George E, Meadows K, Cushnaghan J, Shinmei M et al. Intra-articular hyaluronic acid in osteoarthritis of the knee: an investigation into mechanisms of action. Osteoarthr Cartil 1994;2:133–40.PubMedGoogle Scholar
  72. 72.
    Yoshioka M, Shimizu C, Harwood FL, Coutts RD, Amiel D. The effects of hyaluronan during the development of osteoarthritis. Osteoarthr Cartil 1997;5:251–60.PubMedGoogle Scholar
  73. 73.
    Shimazu A, Jikko A, Iwamoto M, Koike T, Yan W, Okada Y et al. Effects of hyaluronic acid on the release of proteoglycan from the cell matrix in rabbit chondrocyte cultures in the presence and absence of cytokines. Arthritis Rheum 1993;36:247–53.PubMedGoogle Scholar
  74. 74.
    Homandberg GA, Hui F, Wen C, Kuettner KE, Williams JM. Hyaluronic acid suppresses fibronectin fragment mediated cartilage chondrolysis: I. In vitro. Osteoarthr Cartil 1997;5(5):309–19.PubMedGoogle Scholar
  75. 75.
    Kang Y, Eger W, Koepp H, Williams JM, Kuettner KE, Homandberg GA. Hyaluronan suppresses fibronectin fragment-mediated damage to human cartilage explant cultures by enhancing proteoglycan synthesis. J Orthopaed Res 1999;17(6):858–69.Google Scholar
  76. 76.
    Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum 2002;32(1):10–37.PubMedGoogle Scholar
  77. 77.
    Williams JM, Plaza V, Hui F, Wen C, Kuettner KE, Homandberg GA. Hyaluronic acid suppresses fibronectin fragment mediated cartilage chondrolysis: II. In vivo. Osteoarthr Cartil 1997;5(4):235–40.PubMedGoogle Scholar
  78. 78.
    Pasquali Ronchetti I, Guerra D, Taparelli F, Boraldi F, Bergamini G, Mori G et al. Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methylprednisolone acetate (Depomedrol) in osteoarthritis. Rheumatology 2001; 40:158–69.PubMedGoogle Scholar
  79. 79.
    Cubukcu D, Ardic F, Karabulut N, Topuz O. Hylan G-F 20 efficacy on articular cartilage quality in patients with knee osteoarthritis: clinical and MRI assessment. Clin Rheumatol 2005;24(4):336–41. Epub 2004 Dec 14.PubMedGoogle Scholar
  80. 80.
  81. 81.
    Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther 2003;5(2):54–67. Epub 2003 Jan 14.PubMedGoogle Scholar
  82. 82.
    Punzi L, Schiavon F, Cavasin F, Ramonda R, Gambari PF, Todesco S. The Influence of intraarticular hyaluronic acid on PGE2 and cAMP of synovial fluid. Clin Exp Rheumatol 1989;7:247–50.PubMedGoogle Scholar
  83. 83.
    Tobetto K, Yasui T, Ando T, Hayaishi M, Motohashi N, Shinogi M et al. Inhibitory effects of hyaluronan on [14C]arachidonic acid release from labeled human synovial fibroblasts. Jpn J Pharmacol 1992;60:79–84.PubMedGoogle Scholar
  84. 84.
    Yasui T, Akatsuka M, Tobetto K, Hayaishi M, Ando T. The effect of hyaluronan on ­interleukin-1α induced prostaglandin-E2 production in human osteoarthritis synovial cells. Agents Actions 1992;37:155–6.PubMedGoogle Scholar
  85. 85.
    Presti D, Scott JE. Hyaluronan-mediated protective effect against cell damage caused by enzymatically produced hydroxyl (OH) radicals is dependent on hyaluronan molecular mass. Cell Biochem Funct 1994;12:281–8.PubMedGoogle Scholar
  86. 86.
    Comer JS, Kincaid SA, Baird AN, Kammermann JR, Hanson RR Jr, Ogawa Y. Immunolocalization of stromelysin, tumor necrosis factor (TNF) alpha, and TNF receptors in atrophied canine articular cartilage treated with hyaluronic acid and transforming growth factor beta. Am J Vet Res 1996;57:1488–96.PubMedGoogle Scholar
  87. 87.
    Hirota W. Intra-articular injection of hyaluronic acid reduces total amounts of leukotriene C4, 6-keto-prostaglandin F1alpha, prostaglandin F2alpha and interleukin-1beta in synovial fluid of patients with internal derangement in disorders of the temporomandibular joint. Br J Oral Maxillofac Surg 1998;36:35–8.PubMedGoogle Scholar
  88. 88.
    Takahashi K, Goomer RS, Harwood F, Kubo T, Hirasawa Y, Amiel D. The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1beta (IL-1beta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthr Cartil 1999;7:182–90.PubMedGoogle Scholar
  89. 89.
    Nonaka T, Kikuchi H, Ikeda T, Okamoto Y, Hamanishi C, Tanaka S. Hyaluronic acid inhibits the expression of u-PA, PAI-1, and u-PAR in human synovial fibroblasts of osteoarthritis and rheumatoid arthritis. J Rheumatol 2000;27:997–1004.PubMedGoogle Scholar
  90. 90.
    Goto M, Hanyu T, Yoshio T, Matsuno H, Shimizu M, Murata N et al. Intra-articular injection of hyaluronate (SI-6601D) improves joint pain and synovial fluid prostaglandin E2 levels in rheumatoid arthritis: a multicenter clinical trial. Clin Exp Rheumatol 2001;19:377–83.PubMedGoogle Scholar
  91. 91.
    Pellitier JP, Martel-Pelletier J. The pathophysiology oof osteoarthritis and the implication of the use of hyaluronan and hylan as therapeutic agents in viscosupplementation. J Rheumatol 1993;20(suppl 39):19–24.Google Scholar
  92. 92.
    Yasui T, Akatsuka M, Tobetto K, Umemoto J, Ando T, Yamashita K et al. Effects of hyaluronan on the production of stromelysin and tissue inhibitor of metalloproteinase-1 (TIMP-1) in bovine articular chondrocytes. Biomed Res 1992;13:343–8.Google Scholar
  93. 93.
    Fukuda K, Takayama M, Ueno M, Oh M, Asada S, Kumano F, Tanaka S. Hyaluronic acid inhibits interleukin-1-induced superoxide anion in bovine chondrocytes. Inflamm Res 1997;46:114–7.PubMedGoogle Scholar
  94. 94.
    Fukuda K, Oh M, Asada S, Hara F, Matsukawa M, Otani K, Hamanishi C. Sodium hyaluronate inhibits interleukin-1-evoked reactive oxygen species of bovine articular chondrocytes. Osteoarthr Cartil 2001;9:390–2.PubMedGoogle Scholar
  95. 95.
    Sato H, Takahashi T, Ide H, Fukushima T, Tabata M, Sekine F et al. Antioxidant activity of synovial fluid, hyaluronic acid, and two subcomponents of hyaluronic acid. Arthritis Rheum 1988;31:63–71.PubMedGoogle Scholar
  96. 96.
    Moseley R, Leaver M, Walker M, Waddington RJ, Parsons D, Chen WYJ, Embery G. Comparison of the antioxidant properties of HYAFF®-11p75 AQUACEL® and hyaluronan towards reactive oxygen species in vitro. Biomaterials 2002;23:2255–64.PubMedGoogle Scholar
  97. 97.
    Takahashi K, Hashimoto S, Kubo T, Hirasawa Y, Lotz M, Amiel D. Hyaluronan suppressed nitric oxide production in the meniscus and synovium of rabbit osteoarthritis model. J Orthop Res 2001;19:500–3.PubMedGoogle Scholar
  98. 98.
    Peluso G, Perbellini A, Tajana G. The effect of high and low molecular weight hyaluronic acid on mitogen-induced lymphocyte proliferation. Curr Ther Res 1990;47:437–43.Google Scholar
  99. 99.
    Darzynkiewicz Z, Balazs EA. Effect of connective tissue intercellular matrix on lymphocyte stimulation. 1. Suppression of lumphocyte stimulation by hyaluronic acid. Exp Cell Res 1971;66:113–23.PubMedGoogle Scholar
  100. 100.
    Corrado EM, Peluso GF, Gigliotti S, De Durante C, Palmieri D, Savoia M et al. The effects of intra-articular administration of hyaluronic acid on osteoarthritis of the knee: A clinical study with immunological and biochemical evaluations. Eur J Rheumatol Inflamm 1995;15(1):47–56.Google Scholar
  101. 101.
    Hakansson L, Hallgren R, Verge P. Regulation of granulocyte function by hyaluronic acid. In vitro and in vivo effects on phagocytosis, locomotion, and metabolism. J Clin Invest 1980;66:298–305.PubMedGoogle Scholar
  102. 102.
    Partsch G, Schwaarzer C, Neumuller J, Dunky A, Petera P, Bröll H et al. Modulation of the migration and chemotaxis of PMN cells by hyaluronic acid. Z Rheumatol 1989;48:123–8.PubMedGoogle Scholar
  103. 103.
    Pisko E, Turner R, Soderstrom L, Panetti M. Inhibition of neutrophils, phagocytosis and enzyme release by hyaluronic acid. Clin Exp Rheumatol 1983;1:1–14.Google Scholar
  104. 104.
    Forrester J, Balazs E. Inhibition of phagocytosis by high molecular weight hyaluronate. Immunology 1980;40:435–43.PubMedGoogle Scholar
  105. 105.
    Balazs EA, Darzynkiewicz Z. The Efffect of Hyaluronic Acid on Fibroblasts, Mononuclear Phagocytes and Lumphocytes. In Kulonen E, Pikkarainen J, eds. Biology of the Fibroblast. London: Academic; 1973:237–52.Google Scholar
  106. 106.
    Sezgin M, Demirel AC, Karaca C, Ortancil O, Ulkar GB, Kanik A et al. Does hyaluronan affect inflammatory cytokines in knee osteoarthritis? Rheumatol Int 2005;25(4):264–9.PubMedGoogle Scholar
  107. 107.
    Shimizu M, Yasuda T, Nakagawa T, Yamashita E, Julovi SM, Hiramitsu T et al. Hyaluronan inhibits matrix metalloproteinase-1 production by rheumatoid synovial fibroblasts stimulated by proinflammatory cytokines. J Rheumatol 2003; 30(6):1164–72.PubMedGoogle Scholar
  108. 108.
    Wiig ME, Amiel D, VandeBerg J, Kitabayashi L, Harwood FL, Arfors KE. The early effect of high molecular weight hyaluronan (hyaluronic acid) on anterior cruciate ligament healing: an experimental study in rabbits. J Orthop Res 1990;8(3):425–34.PubMedGoogle Scholar
  109. 109.
    Larsen N, Lombard K, Parent E, Balazs E. Effect of hylan on cartilage and chondrocyte cultures. J Orthoped Res 1992;10:23–32.Google Scholar
  110. 110.
    Hulmes DJS, Marsden ME, Strachan RK, Harvery RE, McInnes N, Gardner DL. Intra-articular hyaluronate in experimental rabbit osteoarthritis can prevent changes in cartilage proteoglycan content. Osteoarthr Cartil 2004;12:232–8.PubMedGoogle Scholar
  111. 111.
    Takahashi K, Hashimoto S, Kubo T, Hirasawa Y, Lotz M, Amiel D. Effect of hyaluronan on chondrocyte apoptosis and nitric oxide production in experimentally induced osteoarthritis. J Rheumatol 2000;27:1713–20.PubMedGoogle Scholar
  112. 112.
    Lisignoli G, Grassi F, Zini N, Toneguzzi S, Piacentini A, Guidolin D et al. Anti-fas-induced apoptosis in chondrocytes reduced by hyaluronan. Evidence for CD44 and CD54 (Intercellular Adhesion Molecule 1) involvement. Arthritis Rheum 2001;44:1800–7.PubMedGoogle Scholar
  113. 113.
    Swanstrom OG. Hyaluronate (hyaluronic acid) and its use. In Milne FJ, ed. Proceedings of the 24th Annual Meeting of the American Association of Equine Practioners. Lexington, KY: American Association of Equine Practitioners; 1978:345–8.Google Scholar
  114. 114.
    Nizolek DJ, White KK. Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease. A review. Cornell Vet 1981;71(4):355–75.PubMedGoogle Scholar
  115. 115.
    Forrester JV, Lackie JM. Effect of hyaluronic acid on neutrophil adhesion. J Cell Sci 1981;50:329–44.PubMedGoogle Scholar
  116. 116.
    Tobetto K, Nakai K, Akatsuka M, Yasui T, Ando T, Hirano S. Inhibitory effects of hyaluronan on neutrophil-mediated cartilage degradation. Connect Tissue Res 1993;29:181–90.PubMedGoogle Scholar
  117. 117.
    Balazs E, Briller S, Denlinger J. Na-hyaluronate molecular size variations in equine arthritis and human arthritic synovial fluids and the effect on phagocytic cells. In Talbott J, ed. Seminars in Arthritis and Rheumatism. New York: Grune & Stratton; 1981: Vol. 11:141–3.Google Scholar
  118. 118.
    Pozo MA, Balazs EA, Belmonte C. Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. Exp Brain Res 1997;116(1):3–9.PubMedGoogle Scholar
  119. 119.
    de la Peña E, Pecson B, Schmidt RF, Belmonte C. Effects of hylans on the response characteristics of mechanosensitive ion channels. Presented at the 9th World Congress on Pain, Vienna, Austria, 1999.Google Scholar
  120. 120.
    Aihara S, Murakami N, Ishii R, Kariya K, Azuma Y, Hamada K et al. Effects of sodium hyaluronate on the nociceptive response of rats with experimentally induced arthritis. Nippon Yakurigaku Zasshi 1992;100:359–65.PubMedGoogle Scholar
  121. 121.
    Moore AR, Willoughby DA. Hyaluronan as a drug delivery system for diclofenac: a hypothesis­ for mode of action. Int J Tissue React 1995;17:153–6.PubMedGoogle Scholar
  122. 122.
    Asheim A, Lindblad G. Intra-articular treatment of arthritis in run horses with sodium hyaluronate. Acta Vet Scand 1976;(Suppl 17):379–94.PubMedGoogle Scholar
  123. 123.
    Namiki O, Toyoshima H, Morisaki N. Therapeutic effect of intra-articular injection of high molecular weight hyaluronic acid on osteoarthritis of the knee. Int J Clin Pharmacol Ther Toxicol 1982;20:501–7.PubMedGoogle Scholar
  124. 124.
    Tew WP. Sodium hyaluronate and the treatment of equine joint disorders. In Milne FJ, ed. Proceedings of the 30th Annual Meeting of the American Association of Equine Practioners. Lexington, KY; 1984:67–86.Google Scholar
  125. 125.
    Cannon JH. Clinical evaluation of intra-articular sodium hyaloronate in the Thoroughbred race horse. J Equine Vet Sci 1985;5:147–8.Google Scholar
  126. 126.
    Irwin DHG. Sodium hyaloronate in equine traumatic arthritis. J S Afr Vet Assoc 1980;50:231–3.Google Scholar
  127. 127.
    Nizolek DJH, White KK. Corticosteriod and hyaluronic acid treatments in equine degenerative joint disease: a review. Cornell Vet 1981;71:355–75.PubMedGoogle Scholar
  128. 128.
    Galley RH. The use of hyaluronic acid in the race horse. In Milne FJ, ed. Proceedings of the 32nd Annual Meeting of the American Association of Equine Practioners, Lexington, KY; 1986:657–61.Google Scholar
  129. 129.
    Balazs E. The physical properties of synovial fluid and the specific role of hyaluronic acid. In Heflet AJ, ed. Disorders of the Knee. Philadelphia, PA: J B Lippincott; 1982:61–74.Google Scholar
  130. 130.
    Mensitieri M, Ambrosio L, Iannace S, Nicolais L. Viscoelastic evaluation of different knee osteoarthritis therapies. J Mat Sci Mat Med 1995;6:130–7.Google Scholar
  131. 131.
    Grecomoro G, La Sala F, Francavilla G. Rheologic changes in the synovial fluid of patients with gonarthritis induced by intraarticular infiltration of hyaluronic acid. Int J Tissue React 2001;23(2):67–71.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Todd P. Stitik
    • 1
  • Jong H. Kim
  • Gregory Gazzillo
  • Charles Lee
  1. 1.Department of Physical Medicine and RehabilitationNew Jersey Medical SchoolNewarkUSA

Personalised recommendations